James H. Reamer

Array ( [id] => 14993619 [patent_doc_number] => 20190315767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => TRICYCLIC ASK1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/382936 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53995 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382936 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321244 [patent_doc_number] => 10781200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Therapeutic inhibitory compounds [patent_app_type] => utility [patent_app_number] => 16/382070 [patent_app_country] => US [patent_app_date] => 2019-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66748 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435231 [patent_doc_number] => 20200031799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => THERAPEUTIC INHIBITORY COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/373391 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16373391 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17697048 [patent_doc_number] => 11370758 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => IDO-TDO dual inhibitor and related methods of use [patent_app_type] => utility [patent_app_number] => 16/361908 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 16 [patent_no_of_words] => 21895 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696731 [patent_doc_number] => 10604532 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases [patent_app_type] => utility [patent_app_number] => 16/360811 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48954 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16360811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769316 [patent_doc_number] => 11401241 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease [patent_app_type] => utility [patent_app_number] => 16/982745 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 15879 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18102382 [patent_doc_number] => 11542257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-03 [patent_title] => Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof [patent_app_type] => utility [patent_app_number] => 16/982354 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 13135 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16982354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15245177 [patent_doc_number] => 10508101 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Protein kinase C inhibitors and methods of their use [patent_app_type] => utility [patent_app_number] => 16/354416 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 32339 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 256 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16354416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896739 [patent_doc_number] => 20190292135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS [patent_app_type] => utility [patent_app_number] => 16/297190 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -61 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875499 [patent_doc_number] => 11447500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Thienopyridine derivatives and pharmaceutical composition comprising same [patent_app_type] => utility [patent_app_number] => 16/638668 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 17840 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16642031 [patent_doc_number] => 10919865 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith [patent_app_type] => utility [patent_app_number] => 16/291193 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67870 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621412 [patent_doc_number] => 20210040065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => NOVEL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/977251 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16977251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17756231 [patent_doc_number] => 11396515 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => Pyran fused ring compound, preparation method therefor and use thereof [patent_app_type] => utility [patent_app_number] => 16/616340 [patent_app_country] => US [patent_app_date] => 2019-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12878 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553259 [patent_doc_number] => 20200061041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES [patent_app_type] => utility [patent_app_number] => 16/289311 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19209479 [patent_doc_number] => 11998513 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Two-part nitric oxide generating topical compositions [patent_app_type] => utility [patent_app_number] => 16/976382 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 40 [patent_no_of_words] => 12836 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16976382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16230494 [patent_doc_number] => 10738032 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors [patent_app_type] => utility [patent_app_number] => 16/285762 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 15742 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16285762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18315080 [patent_doc_number] => 11629149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-18 [patent_title] => 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza [patent_app_type] => utility [patent_app_number] => 16/975784 [patent_app_country] => US [patent_app_date] => 2019-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28630 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621435 [patent_doc_number] => 20210040088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => INHIBITORS OF EGFR AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/970931 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39223 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715427 [patent_doc_number] => 20190248777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/272506 [patent_app_country] => US [patent_app_date] => 2019-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16272506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504728 [patent_doc_number] => 20200383984 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE [patent_app_type] => utility [patent_app_number] => 16/968273 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968273 [rel_patent_id] =>[rel_patent_doc_number] =>)